Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a radioactive antibody seek out and destroy Hard-to-Treat tumors?

NCT ID NCT06980519

Disease control Sponsor: Monopar Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused) This study
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This program provides access to an investigational therapy called MNPR-101-PCTA-177Lu for people with advanced solid tumors that have not responded to existing treatments. The therapy combines an antibody with a radioactive payload, designed to bind to a protein called uPAR found on many solid tumors and deliver radiation directly to cancer cells. Participants first undergo a PET/CT scan with a companion imaging agent to confirm their tumors express uPAR. The goal is to see whether this targeted approach can control tumor growth in patients who have run out of standard options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MNPR-101-PCTA-177Lu, a monoclonal antibody attached to a radioactive molecule that targets and delivers radiation to uPAR-positive solid tumors
What this could lead to
If this treatment works, it could offer a new option for people with advanced solid tumors that have stopped responding to standard therapies, potentially slowing tumor growth or shrinking tumors.
What could go wrong
This is an expanded access program, not a controlled trial, so its results are less definitive. The treatment may cause side effects from radiation, and its effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Participated in the Expanded Access Program (EAP) IST-00Ca study * Histologically or cytologically confirmed locally advanced or metastatic solid tumor cancer that is refractory to existing therapy(ies) known to provide clinical benefit, or for which no standard treatment is available, or is contraindicated * Ability to understand and willingness to sign a written informed consent document Key Exclusion Criteria: * Chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy), or immunotherapy within 14 days prior to administration of MNPR-101-PCTA-177Lu * Continuing ≥ Grade 3 adverse reactions from prior systemic therapy (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) * Prior treatment with any radiopharmaceutical or investigational agents within 4 weeks or 5 half-lives, whichever is longer, prior to administration of the first dose of MNPR-101-PCTA-177Lu other than MNPR-101-DFO\*-89Zr * Evidence of impaired organ function, particularly bone marrow, liver, kidney, or heart, according to specific test parameters * Presence of other serious, non-malignant diseases or any other condition that, in the opinion of the investigator, could interfere with the objectives of the study, participant safety, or compliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Oncology Solid tumor Solid tumor cancer Upar-positive solid tumor Urokinase plasminogen activator receptor-positive solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Excel Diagnostics & Nuclear Oncology Center

    Houston, Texas, 77042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.